dicloxacillin (pathocil) Report issue

Small molecule Approved FDA
AACT ChEMBL DrugBank Drug Central Drugs@FDA KEGG MeSH PubChem repoDB

Active Ingredient History

NOW
  • Now
Dicloxacillin sodium USP is a semisynthetic antibiotic substance which resists destruction by the enzyme penicillinase (beta-lactamase). It is monosodium (2S,5R,6R)-6-[3-(2,6-dichlorophenyl)-5-methyl-4- isoxazolecarboxamido]-3,3-dimethyl-7-oxo-4-thia-1-azabicyclo [3.2.0]heptane-2-carboxylate monohydrate. Like other β-lactam antibiotics, dicloxacillin acts by inhibiting the synthesis of bacterial cell walls. It inhibits cross-linkage between the linear peptidoglycan polymer chains that make up a major component of the cell wall of Gram-positive bacteria. Dicloxacillin is administered orally via capsule form or powder for reconstitution.   NCATS

Chemistry

  • SMILES: Cc1onc(-c2c(Cl)cccc2Cl)c1C(=O)N[C@@H]1C(=O)N2[C@@H]1SC(C)(C)[C@@H]2C(=O)O
  • InChIKey: YFAGHNZHGGCZAX-JKIFEVAISA-N
  • Mol. Mass: 470.33
  • ALogP: 3.2
  • ChEMBL Molecules:
    dicloxacillin  
    dicloxacillin sodium  
More Chemistry

Pharmacology

Drug Pricing (per unit)

Australia

$0.1522 - $0.3247

United States

$0.3042 - $1.1890
More Pricing Detail

Note: This drug pricing data is preliminary, incomplete, and may contain errors.

Alternative names

(2s,5r,6r)-6-({[3-(2,6-dichlorophenyl)-5-methyl-1,2-oxazol-4-yl]carbonyl}amino)-3,3-dimethyl-7-oxo-4-thia-1-azabicyclo[3.2.0]heptane-2-carboxylic acid | brl-1702 | dicloxacilina | dicloxacillin | dicloxacillina | dicloxacilline | dicloxacillin sodium | dicloxacillin sodium hydrate | dicloxacillinum | dicloxacycline | dycill | dynapen | p-1011 | pathocil | r-13423

Organizations (17)

Research & Development (10)

Organization Org Type FDA approvals Clinical Trials involvement Org ID Force Sort

Marketing (7)

Organization Org Type FDA approvals Clinical Trials involvement Org ID Force Sort

Indications (15)

Approved Indications (4)


 

Bronchitis (approved 1968)

Infections

Pneumonia (approved 1968)

Staphylococcal Infections (approved 1968)

Experimental Indications - Clinical Trial Phases 1-4 (12)


 

Arthritis, Infectious (Phase 4)

Bacteremia (Phase 4)

Bacterial Infections (Phase 3)

Bone Diseases, Infectious (Phase 4)

Dermatitis, Atopic (Phase 4)

Drug Interactions (Phase 1)

Eczema (Phase 4)

Endocarditis (Phase 4)

Gram-Positive Bacterial Infections (Phase 3)

Healthy Volunteers (Phase 1)

Infections (Phase 4)

Osteomyelitis (Phase 4)

Overview

  • Highest Phase: Phase 4
  • # of Trials: 8
  • # of Trial Organizations: 10

Trials by Phase

Trial Phase Start Date Organizations Indications

Feedback

Data collection and curation is an ongoing process for CDEK - if you notice any information here to be missing or incorrect, please let us know! When possible, please include a source URL (we verify all data prior to inclusion).

Report issue